PIK3CA and glioblastoma: Thus far, only a few pan-PI3K inhibitors (buparlisib, pilaralisib and sonolisib) and dual PI3K/mTOR inhibitors (paxalisib, dactolisib, voxtalisib, PQR309) have been evaluated in clinical trials for the treatment of GBM (Table 1and Table 2), among which, buparlisib is the most commonly studied.